Your browser doesn't support javascript.
loading
In silico drug repositioning based on drug-miRNA associations.
Zhou, Xu; Dai, Enyu; Song, Qian; Ma, Xueyan; Meng, Qianqian; Jiang, Yongshuai; Jiang, Wei.
Afiliação
  • Zhou X; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
  • Dai E; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
  • Song Q; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
  • Ma X; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
  • Meng Q; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
  • Jiang Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, P. R. China.
  • Jiang W; Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing, P. R. China.
Brief Bioinform ; 21(2): 498-510, 2020 03 23.
Article em En | MEDLINE | ID: mdl-30753359
ABSTRACT
Drug repositioning has become a prevailing tactic as this strategy is efficient, economical and low risk for drug discovery. Meanwhile, recent studies have confirmed that small-molecule drugs can modulate the expression of disease-related miRNAs, which indicates that miRNAs are promising therapeutic targets for complex diseases. In this study, we put forward and verified the hypothesis that drugs with similar miRNA profiles may share similar therapeutic properties. Furthermore, a comprehensive drug-drug interaction network was constructed based on curated drug-miRNA associations. Through random network comparison, topological structure analysis and network module extraction, we found that the closely linked drugs in the network tend to treat the same diseases. Additionally, the curated drug-disease relationships (from the CTD) and random walk with restarts algorithm were utilized on the drug-drug interaction network to identify the potential drugs for a given disease. Both internal validation (leave-one-out cross-validation) and external validation (independent drug-disease data set from the ChEMBL) demonstrated the effectiveness of the proposed approach. Finally, by integrating drug-miRNA and miRNA-disease information, we also explain the modes of action of drugs in the view of miRNA regulation. In summary, our work could determine novel and credible drug indications and offer novel insights and valuable perspectives for drug repositioning.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / MicroRNAs / Reposicionamento de Medicamentos Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / MicroRNAs / Reposicionamento de Medicamentos Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article